ライフサイエンスコーパス: peripheral edema

1 d reductions in the presence and severity of peripheral edema.

2 in congestive heart failure, arrhythmia, and peripheral edema.

3 The most common toxicities were fatigue and peripheral edema.

4 anxiety, pharyngitis, sinus congestion, and peripheral edema.

5 ely lead to pulmonary congestion, ascites or peripheral edema.

6 administration was associated with increased peripheral edema.

7 rse vasodilatory effects such as headache or peripheral edema.

8 el movements a day, weight loss of 10 kg and peripheral edema.

9 olitinib were nausea, fatigue, vomiting, and peripheral edema.

10 ual hallucinations (15 [23.8%] vs 1 [1.7%]), peripheral edema (15 [23.8%] vs 0), and dizziness (14 [2

11 s) were peripheral sensory neuropathy (30%), peripheral edema (16%), and fatigue (14%); the most comm

12 europathy, 3% and 0.8%; fatigue, 5% and 12%; peripheral edema, 3.8% and 1.5%; and diarrhea, 2% and 10

13 cough (39%), nausea (32%), arthralgia (31%), peripheral edema (31%), and hypertension (30%).

14 s) were peripheral sensory neuropathy (50%), peripheral edema (32%), and nausea (24%).

15 a total of 6394 composite renal events (2670 peripheral edema, 3489 hypertension, 235 renal dysfuncti

16 ypokalemia (49.3%), neutropenia (47.9%), and peripheral edema (45.1%).

17 receiving savolitinib plus osimertinib were peripheral edema (46.0%), nausea (40.5%), and diarrhea (

18 inotransferase (60%), hypoalbuminemia (55%), peripheral edema (51%), and thrombocytopenia (49%).

19 e events in zibotentan-treated patients were peripheral edema (52.7%), diarrhea (35.4%), alopecia (33

20 , and 5% in arms A, B, and C, respectively), peripheral edema (71%, 51%, and 22% in arms A, B, and C,

21 rk Heart Association class III/IV (95%), had peripheral edema (95%), and previous hospitalization for

22 re frequent with C25; peripheral neuropathy, peripheral edema, alopecia, and nail disorders were more

23 d anticonvulsants; xerostomia with TCAs; and peripheral edema and burning sensation with pregabalin a

24 lbumin:creatinine ratio (UACR), proteinuria, peripheral edema and fatigue.

25 s, which were accompanied by improvements in peripheral edema and functional status.

26 ted that for rofecoxib the adverse risks for peripheral edema and hypertension were evident by the en

27 onist treatment of humans is associated with peripheral edema and increased heart failure.

28 er nonhematologic toxicities, which included peripheral edema and neuropathy, are uncommon, and the a

29 Because myocardial and peripheral edema and systemic hypotension occur frequent

30 Peripheral edema and weight gain were observed in two of

31 ld adverse effects included malaise/fatigue, peripheral edema, and hyperglycemia.

32 Somnolence, dizziness, ataxia, peripheral edema, and infection were all more frequent i

33 Neutropenia, peripheral edema, and liver function test abnormalities

34 increased risk of congestive heart failure, peripheral edema, and several other noncardiac phenotype

35 Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more

36 lyzed were elevated central venous pressure, peripheral edema, ascites, and use of inotropes.

37 She decompensated with jaundice, peripheral edema, ascites, encephalopathy, coagulopathy,

38 (or lymphadenopathy), endocrinopathy, edema (peripheral edema, ascites, or effusions), and skin chang

39 with substantial concomitant hemorrhage and peripheral edema by E17.5dpc, resulting in mortality imm

40 body weight (days 1 and 7 or discharge), and peripheral edema (day 7 or discharge).

41 patients were skin-related toxicity, nausea, peripheral edema, diarrhea, pruritis, and fatigue.

42 The most common adverse events included peripheral edema, disease progression, and peripheral is

43 recurrent episodes of hypotensive shock and peripheral edema due to widespread vascular leakage in p

44 verse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across arms).

45 th anemia (grade 1 to 2, 35%; grade 3, 10%), peripheral edema (grade 1 to 2, 37%; grade 3, 2%), and f

46 up than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia

47 Atrial fibrillation, contusion, diarrhea, peripheral edema, hemorrhage, muscle spasms, and pneumon

48 rial fibrillation, diabetes mellitus, rales, peripheral edema, higher New York Heart Association clas

49 Rash, peripheral edema, hyperglycemia, and hyperlipidemia were

50 All NSAIDs may produce peripheral edema, hypertension, and potentiate warfarin.

51 were associated with hepatic congestion and peripheral edema, intracardiac thrombi, and premature mo

52 acral erythema (n = 1), neuropathy (n = 1), peripheral edema (n = 1), and diarrhea (n = 1).

53 Side effects of IL-11 were mild (peripheral edema, n = 7; conjunctival injection, n = 7;

54 function, and this could explain some of the peripheral edema noted clinically with these agents.

55 Peripheral edema occurred in 9% of subjects receiving pl

56 w the clinical components of congestion (eg, peripheral edema, orthopnea) contribute to outcomes afte

57 ul decongestion was defined as an absence of peripheral edema, pulmonary rales, and jugular venous pr

58 ecoxib was associated with increased risk of peripheral edema (RR, 1.43; 95% CI, 1.23-1.66), hyperten

59 macitentan than with placebo were headache, peripheral edema, skin ulcer, anemia, upper respiratory

60 ted with urinary retention, arthralgias, and peripheral edema, subsequently developed acute lower-ext

61 age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, serum sodium,

62 -losing enteropathy, plastic bronchitis, and peripheral edema that may involve the lymphatic circulat

63 ight gain, pleural or pericardial effusions, peripheral edema, thromboembolic events, and intermitten

64 2 pillows=2 points, <2 pillows=0 points) and peripheral edema (trace=0 points, moderate=1 point, seve

65 insufficiency manifested by new ascites and peripheral edema, treated with diuretics, a low-salt die

66 Marked ascites out of proportion to peripheral edema usually develops as a typical feature o

67 Mild peripheral edema was seen in 15% of patients and was tre

68 ates were similar, and a higher incidence of peripheral edema was the only apparent side effect of fe

69 rn after being linked with increased risk of peripheral edema, weight gain, and adverse cardiovascula

70 Rash, diarrhea, and peripheral edema were the most common toxic effects in t

71 s, such as rhinitis, headache, asthenia, and peripheral edema, were reversible on drug discontinuatio

72 , fatigue) and volume overload (eg, dyspnea, peripheral edema), worsening eGFR, metabolic acidosis, a